Global Rheumatoid Arthritis Drugs Market 2018-2022 | Need for Affordable Biologic Drugs for Rheumatoid Arthritis Impacting Market Growth | Technavio

Dec. 3, 2018 15:03 UTC

LONDON--(BUSINESS WIRE)-- The global rheumatoid arthritis (RA) drugs market 2018-2022 is expected to post a CAGR of close to 8% during the forecast period, according to the latest market research report by Technavio.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181203005377/en/

Technavio predicts the global rheumatoid arthritis drugs market to post a CAGR of close to 8% by 202 ...

Technavio predicts the global rheumatoid arthritis drugs market to post a CAGR of close to 8% by 2022. (Graphic: Business Wire)

A key factor driving the growth of the market is a need for affordable biologic drugs for RA. Unlike conventional DMARDs, such as NSAIDs, that simply give symptomatic relief, biologic drugs are more efficient in the management of RA. However, biologic drugs are associated with a high cost of development and are expensive for patients. Different programs, such as state-run prescription-drug discount programs, have been introduced to reduce the rheumatoid arthritis drugs cost and make them affordable for patients. Similarly, reimbursements are also provided by Medicaid or Medicare programmers, which are federally sponsored health-care program.

This market research report on the global rheumatoid arthritis drugs market 2018-2022 also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

In this report, Technavio highlights the high cost of rheumatoid arthritis drugs as one of the key emerging trends in the global rheumatoid arthritis drugs market:

Global rheumatoid arthritis drugs market: High cost of RA drugs

The cost of rheumatoid arthritis drugs and NSAIDs is less compared with biologics. However, the long-term use of these drugs can cause significant disease burden. Rheumatoid arthritis drugs management is associated with a high cost. However, the lack of early intervention can increase the cost of rheumatoid arthritis drugs due to the risks of disability. The entry of new oral drugs and drugs that can be self-administered may reduce the cost for patients. As new biologics enter the market, health plans will need to consider how coverage channels, including rebates or other discounts offered under pharmacy benefit structure, will impact future costs.

“The wholesale prices of the most common rheumatoid arthritis drugs, such as HUMIRA and Enbrel, have increased by almost 70% in the US. The first drug for the treatment of RA was $10,000. Though there are a variety of substitutes available in the market, the price of this drug is now worth more than $40,000,” says a senior analyst at Technavio.

Global rheumatoid arthritis drugs market: Segmentation analysis

This market research report segments the global rheumatoid arthritis drugs market by type of molecule (biologics and small molecules) and geographical regions (APAC, EMEA, and the Americas).

The Americas led the market in 2017 with a market share of more than 65%, followed by EMEA and APAC respectively. The dominance of the Americas can be attributed to the need for affordable biologics for RA and unmet needs of safer biologics for RA. The prevalence of RA in North-America (Canada and the US) and in northern and middle Europe is high compared with southern Europe.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

 

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

 

 
 

Source: Technavio Research

Smart Multimedia Gallery

Technavio predicts the global rheumatoid arthritis drugs market to post a CAGR of close to 8% by 2022. (Graphic: Business Wire)

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20181203005377/en

Back to news